Subscribe to Newsletter

Jan van de Winkel

The Power List 2021 – Biopharmaceuticals

President and CEO at Genmab

After co-founding Genmab and serving as President, Research and Development and Chief Scientific Officer, van de Winkel was appointed President and Chief Executive Officer in 2010. Under his leadership, Genmab has created three antibody medicines that all received Breakthrough Therapy Designations from the FDA and are now commercialized by partners: Darzalex, a backbone therapy for multiple myeloma, commercialized by Janssen; Kesimpta by Novartis; and Tepezza by Horizon Therapeutics.

“We believe that partnerships and collaborations are foundational to accelerate innovation and bring medicines to patients as quickly as possible. It takes an innovation ecosystem with partnerships between biotech and big pharma, academia, research institutes, data sciences companies or medical electronics companies to catalyze break-through innovation.”

Part of the Power List 2021

Find out more

Welcome to our annual celebration of the great and inspirational minds that contribute to the development and manufacture of new medicinal products

Go to The Power List 2021

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine